Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.7093 +0.0147 (+2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ocugen, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis 
From Ocugen
Via GlobeNewswire
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via GlobeNewswire
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
From Ocugen
Via GlobeNewswire
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
From Ocugen
Via GlobeNewswire
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen Appoints Quan A. Vu as Chief Business Officer
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
From Ocugen
Via GlobeNewswire
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022 
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
From Ocugen
Via GlobeNewswire
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
From Ocugen
Via GlobeNewswire
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
From Ocugen
Via GlobeNewswire
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
From Ocugen
Via GlobeNewswire
MarketBeat: Week in Review 8/22 - 8/26
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Are Ocugen or Amarin Good Penny Stocks to Buy?
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing. 
Via MarketBeat
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
LAWSUITS FILED AGAINST OCGN, DKNG and PLL - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal Product Safety
CLASS ACTION UPDATE for OCGN, HMPT and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal Product Safety
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS